HomeProductsPeptidesGHRP-6-5mg

GHRP-6-5mg

1 Vial $29.99 ($29.99)
Sale Most Popular!
2 Vials $59.98 $54.99
Save $4.99 ($54.99)
Sale Best Choice!
3 Vials $89.97 $73.99
Save $15.98 ($73.99)
Grand total

Availability: Ships today if ordered and paid by 7AM EST

GHRP-6 is a synthetic ghrelin/growth hormone secretagogue agonist. It has positive effects on appetite, heart muscle cells, scar formation, and sexual motivation. Animal studies show this orally active growth hormone secretagogue also improves memory function and may help to thwart the neurological effects of Parkinson’s disease.
Where to buy GHRP-6 5mg? Shop now for GHRP-6 5mg with exceptional quality and get more for less with our bulk sales. Quick 48-hour delivery available.

Share

    3rd party checkout COA cust serv Purity shipping

    GHRP-6-5mg Properties

    Chemical Formula: C46H56N12O6
    Molecular Mass: 873.032
    Synonyms: Growth Hormone Releasing Peptide 6, Hexapeptide-2, HWAWFK-NH2, SKF 110679, U 75799E
    PubChem: 9919153
    Total Amount of the Active Ingredient: 5mg (1 vial)
    Shelf Life: 36 months

    Product Quality

    Lab tests are occasionally published on the website. You can have the product you bought from us tested at any HPLC licensed testing facility and if the results are negative, we will refund the following:

    • Cost of HPLC test
    • Total amount of the order + shipping fee

    Peer-Reviewed Studies

    The Peptidic GHS-R antagonist [D-Lys3] GHRP 6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity

    Abstract
    It was demonstrated that estrogen deficiency and consuming high fat (HF) diet enhanced orexigenic activity of ghrelin. Therefore, we hypothesized that antagonizing of ghrelin action would attenuate food intake and body weight in mice obese both from ovariectomy (OVX) and feeding a HF diet.

    Ghrelin receptor antagonist [D-Lys3]GHRP-6 after seven days of subcutaneous treatment markedly decreased food intake in OVX mice fed both HF and standard diets; furthermore, it reduced body weight and blood glucose, insulin and leptin, and increased β-hydroxybutyrate level and uncoupling-protein-1 mRNA in brown adipose tissue. Pair-feeding revealed that effect of [D-Lys3]GHRP-6 was primary anorexigenic. Estrogen supplementation reduced anorexigenic effects of [D-Lys3]GHRP-6. OVX [D-Lys3]GHRP-6 treatment in mice on HF diet resulted in markedly increased circulating level and liver expression of a major metabolic regulator, fibroblast growth factor 21.

    Our data suggest that ghrelin antagonists could be especially beneficial in individuals with common obesity combined with estrogen deficiency.


    Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6)

    Abstract
    Growth hormone (GH) secretion is regulated by a complex system of central and peripheral signals. Recently, a new GH-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) called GHRP-6 which specifically releases GH has been studied. In the present work the mechanism of action of GHRP-6 has been addressed in experimental animal models as well as in obese subjects. GHRP-6 releases GH independently of the hypothalamic factors GHRH and somatostatin and is a powerful GH releaser in obesity.


    Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers

    Abstract
    GHRP-6 is a growth hormone secretagogue that also enhances tissue viability in different organs. In the present work, we studied the pharmacokinetics of this short therapeutic hexapeptide (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,) MW=872.44 Da) in nine male healthy volunteers after a single intravenous bolus administration of 100, 200 and 400 μg/kg of body weight. GHRP-6 was quantified in human plasma by a specific LC-MS method, previously developed and validated following FDA guidelines, using (13)C(3)Ala-GHRP-6 as internal standard (Gil et al., 2012, J. Pharm. Biomed. Anal. 60, 19-25). The Lower Limit of Quantification (5 mg/mL) was reached in all subjects at 12h post-administration, which was sufficient for modeling a pharmacokinetic profile including over 85% of the Area under the Curve (AUC). Disposition of GHRP-6 best fitted a bi-exponential function with R(2) higher than 0.99, according to a mathematic modeling and confirmed by an Akaike index (AIC) lower than that of the corresponding one-compartment model for all subjects. Averaging all three dose levels, the distribution and elimination half-life of GHRP-6 were 7.6 ± 1.9 min and 2.5 ± 1.1h, respectively. These values are coherent with existing data for other drugs whose disposition also fits this model. Dose dependence analysis revealed a noticeable trend for AUC to increase proportionally with administered dose. Atypical GHRP-6 concentration spikes were observed during the elimination phase in four out of the nine subjects studied.


    Shipping

    USA

    Canada

    If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.

    Disclaimer

    The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider.

    In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.

    Note: In some cases wherein the assigned top colors are out of stock, a different top color will be used to ensure that your order will not be delayed. Should you need assistance identifying the peptide vial that you received, please send us an email at [email protected].

    ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

    The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat and/or cure any medical condition, ailment or disease. Bodily introduction of any kind into animals or human is strictly prohibited by law.

    How Many Vials?

    1 Vial, 2 Vials, 3 Vials, 4 Vials, 5 Vials, 10 Vials, 20 Vials, 40 Vials, 100 Vials

    FAQ

    GHRP 6 5mg Vials  

    How to reconstitute GHRP 6 5mg vials?

    GHRP 6 5mg vials contain a peptide powder, which is typically a puck or loose bits due to shipping. To reconstitute a GHRP 6 5mg vials, researchers typically use bacteriostatic water, combining it with the peptide powder according to the specific requirements of their research protocols.

     

    How to dose GHRP 6 5mg?

    The dosing of GHRP 6 5mg in vials form will vary according to the experiment being conducted. We do not provide dosage recommendations as our products are intended for research purposes only.

     

    How to administer GHRP 6 5mg?

    There are multiple methods of administering research products that are under investigation in various studies. The choice of administration technique should align with the specific goals and design of the researcher’s study. We provide products solely for research use, we do not offer advice on administration methods.